Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (23 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15
Grant
1
0
1
0
0
2
Collaboration and reimbursable research and development costs
0
0
0
0
0
0
Sales and services
0
0
0
0
3
3
Total revenues
1
1
1
0
4
5
COSTS OF REVENUES
0
0
0
0
2
2
Research and development
0
0
4
9
24
31
Acquired in-process research and development
0
0
0
0
0
0
Acquired in-process research and development
1
3
0
6
0
24
General and administrative
1
1
2
6
10
20
Intangible amortization
0
0
0
1
2
1
Total costs and operating expenses
2
4
5
22
39
79
Loss from operations
-2
-3
-5
-22
-35
-74
Gain on expiration of derivative liability
0
0
0
0
0
-3
Gain on sale of IgDraSol, net
0
0
0
0
0
69
Loss on equity investments
0
0
0
0
0
-4
Interest expense
0
0
0
0
-2
-2
Interest income
0
0
0
0
0
0
Income (loss) before income tax expense
0
0
-5
-22
-36
-14
Income tax expense (benefit)
0
0
0
0
-2
36
Net loss
0
0
0
-22
-35
-50
Net loss attributable to noncontrolling interests
0
0
0
0
0
-4
Net loss attributable to Sorrento
-2
-3
-5
-22
-35
-46
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Mar 16, 2015 n/a
calculated values,
restated on Mar 15, 2016 n/a
calculated values,
restated on Mar 15, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (42 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash and cash equivalents
5
3
5
32
72
39
Marketable securities
0
0
0
0
0
97
Grants and accounts receivables, net
0
0
0
0
1
1
Income tax receivable
0
0
0
0
0
2
Notes receivable
0
0
0
0
0
0
Prepaid expenses and other, net
0
0
0
1
1
2
Total current assets
6
4
5
33
74
141
Property and equipment, net
0
1
1
2
2
7
Intangibles, net
0
0
0
33
4
4
Goodwill
0
0
0
24
24
21
Investments in common stock
0
0
0
0
10
112
Equity method investments
0
0
0
0
0
58
Long-term assets held for sale
0
0
0
0
27
0
Other, net
0
0
0
0
0
1
Total assets
6
5
7
93
142
344
Liabilities and owners' equity
Accounts payable
0 181799
0 224742
0 439533
2 2153000
2 1656000
1 1339000
Accrued payroll and related
0 54377
0 88510
0 77744
2 1664000
2 1825000
2 2361000
Current portion of deferred compensation
0 0
0 0
0 0
1 904000
2 1893000
1 891000
Accrued expenses
0 167781
0 46087
0 66896
0 385000
1 867000
4 3927000
Acquisition consideration payable
0 0
0 0
0 0
0 0
0 0
12 12000000
Derivative liability
0 0
0 0
0 0
0 0
0 0
6 5520000
Current portion of debt
0 0
0 0
0 0
0 374000
3 3316000
5 4835000
Total current liabilities
1 603957
0 359339
1 584173
5 5480000
10 9557000
31 30873000
Long-term debt
0 0
0 0
0 0
4 4431000
9 8830000
4 4394000
Deferred compensation
0 0
0 0
0 0
1 1497000
1 796000
0 12000
Deferred tax liabilities
0 0
0 0
0 0
14 14248000
2 1709000
49 49341000
Long-Term Liabilities held for sale
0 0
0 0
0 0
0 0
11 10837000
0 0
Deferred revenue
0 200000
0 0
0 0
0 0
1 1024000
111 110900000
Deferred rent and other
0 0
0 0
0 0
0 117000
0 75000
7 7061000
Total liabilities
0 0
0 0
0 0
0 0
33 32828000
203 202581000
Commitments and contingencies
0 0
0 0
0 0
0 0
0 0
0 0
Preferred stock
0 0
0 0
0 0
0 0
0 0
0 0
Common stock
0 25080
0 26235
0 1200
0 2000
0 4000
0 4000
Additional paid-in capital
8 7927244
10 10288245
17 17146530
100 99668000
176 176227000
185 184898000
Accumulated other comprehensive income
0 0
0 0
0 0
0 0
0 0
74 73579000
Stock subscription receivable
0 0
0 0
0 0
0 0
0 0
0 0
Accumulated deficit
-3 -2868500
-6 -6104991
-11 -10950299
-33 -32861000
-68 -67518000
-113 -113329000
Total Sorrento Therapeutics, Inc. stockholders' equity
5 5083824
4 4209489
6 6197431
67 66809000
109 108713000
145 145152000
Noncontrolling interests
0 0
0 0
0 0
0 0
0 0
-4 -4214000
Total equity
0 0
0 0
0 0
0 0
109 108713000
141 140938000
Total liabilities and equity
6 5687781
5 4568828
7 6781604
93 92582000
142 141541000
344 343519000
Remarks restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Apr 1, 2014 n/a restated on Mar 16, 2015 n/a restated on Mar 15, 2016 n/a restated on Nov 30, -1 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (31 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15
Net loss
-2
-3
-5
-22
-35
-50
Depreciation and amortization
0
0
0
1
3
2
Non-cash interest expense
0
0
0
0
0
0
Gain on sale of IgDraSol
0
0
0
0
0
-69
Stock-based compensation
0
0
1
2
4
7
Acquired in-process research and development
0
0
0
2
0
12
Provision for doubtful accounts
0
0
0
0
0
0
Gain on expiration of derivative liability
0
0
0
0
0
3
Loss on equity investments
0
0
0
0
0
4
Deferred tax provision
0
0
0
0
-2
33
Grants and other receivables
0
0
0
0
0
0
Prepaid expenses and other
0
0
0
0
-1
-1
Income tax receivable
0
0
0
0
0
-2
Accounts payable
0
0
0
1
0
-3
Accounts payable-related parties
0
0
0
0
0
0
Deferred revenue
0
0
0
0
0
10
Accrued expenses and other liabilities
0
0
0
0
2
11
Net Cash Used For Operating Activities
-2
-3
-4
-16
-29
-42
Purchases of property and equipment
0
-1
-1
0
-1
-4
Purchases of intangible assets
0
0
0
-1
0
0
Cash received in connection with mergers
0
0
0
0
0
0
Investments in common stock
0
0
0
0
-10
-12
Net cash provided by (used in) investing activities
0
-1
-1
-1
-11
13
Net borrowings under loan and security agreement
0
0
0
7
8
0
Proceeds from issuance of common stock, net of issuance costs and repurchases
3
2
6
38
72
0
Net principal payments under loan and security agreement
0
0
0
0
0
-3
Net payments of deferred compensation
0
0
0
-1
0
-2
Sale of a noncontrolling interest
0
0
0
0
0
0
Proceeds from exercise of stock options
0
0
0
0
0
2
Net cash (used in) provided by financing activities
3
2
6
44
80
-3
Net change in cash and cash equivalents
2
-2
2
27
40
-33
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Mar 27, 2013 n/a
calculated values,
restated on Mar 16, 2015 n/a
calculated values,
restated on Mar 15, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Sumo